How and where to order Medrol, Depo-Medrol (Methylprednisolone) 4 mg, 8 mg, 16 mg, 32 mg tablets or capsules online on Noah's Wish website:
|Prices:||from $0.61 per pill
|Discount:||10% coupon: DFHDCC
|Forms:||4, 8, 16, 32 mg pills
|Type:||Methylprednisolone brand, Medrol generic, Depo-Medrol generic
|Payment:||Visa, Mastercard, AmEx, E-Check (ACH), Bitcoin
|Delivery:||Standard airmail and trackable courier service
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Methylprednisolone (trade names include Medrol, Advantan, Depo-Medrate, Depo-Medrol, Depo-Medrone, Hexilon, Hysone, Ivepred, Lemod-Solu, Medixon, Medrol Dose Pak, Medrol-A, Medrone, Melsone, Meprelon, Mepresone, Cadista Methylprednisolone, Neodrol, Oro-Medrol, Predmet, Predni-M, Solomet, Solu-Medrol, Stenirol, Urbason, Zempred) is a synthetic glucocorticoid (GCS) medication from corticosteroid for topical and systemic use pharmacological groups. This medicine is used for the treatment of various medical conditions, such as skin diseases, allergic disorders, inflammatory conditions, endocrine (hormonal) disorders, autoimmune diseases, certain blood disorders, rheumatic disorders, breathing disorders, asthma, chronic obstructive pulmonary disease (COPD), bronchial inflammation, acute bronchitis, croup, shock, allergic rhinitis, arthritis, rheumatoid arthritis, osteoarthritis, gout, adrenogenital syndrome, ulcerative colitis, lupus, systemic lupus erythematosus, acne, pimples, dermatitis, psoriasis, plaque psoriasis, dermatologic lesion, certain cancers, tumor, multiple sclerosis, transverse myelitis, tuberculosis, vestibular neuronitis, neuralgia, Crohn's disease; to prevent the body from rejecting the embryos for a cycle of in vitro fertilization; for immunosuppression; in veterinary medicine; and for other diseases and medical disorders. It works by preventing the release of some substances in the body that cause inflammation.
Budesonide, Formoterol (Symbicort)
Mefenamic Acid (Ponstel)
Pharmacological and medical categories:
Anti acne medicines
Medications for the treatment of dermatological diseases
Oestrogens and progesterones and related synthetic drugs
Veterinary, pet meds
Weak (group I) corticosteroids
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07A - Corticosteroids, plain
D07AA - Corticosteroids, weak (group I)
D07AA01 - Methylprednisolone
D07AC - Corticosteroids, potent (group III)
D07AC14 - Methylprednisolone Aceponate
D10 - Anti-acne preparations
D10A - Anti-acne preparations for topical use
D10AA - Corticosteroids, combinations for treatment of acne
D10AA02 - Methylprednisolone
H - Systemic hormonal preparations, excl. sex hormones and insulins
H02 - Corticosteroids for systemic use
H02A - Corticosteroids for systemic use, plain
H02AB - Glucocorticoids
H02AB04 - Methylprednisolone
Tuberculosis - A15-A19
Acute Hepatitis A - B15
Other acute viral hepatitis - B17
Malignant neoplasm of bronchus and lung - C34
Follicular [nodular] non-Hodgkin's lymphoma - C82
Diffuse non-Hodgkin's lymphoma - C83
Multiple myeloma and malignant plasma cell neoplasms - C90
Lymphoid leukaemia - C91
Myeloid leukaemia - C92
Other disorders involving the immune mechanism, not elsewhere classified - D89
Adrenogenital disorders - E25
Multiple sclerosis - G35
Other demyelinating diseases of central nervous system - G37
Acute transverse myelitis in demyelinating disease of central nervous system - G37.3
Disorders of vestibular function - H81
Vestibular neuronitis - H81.2
Acute obstructive laryngitis [croup] and epiglottitis - J05
Acute obstructive laryngitis [croup] - J05.0
Acute bronchitis - J20
Vasomotor and allergic rhinitis - J30
Bronchitis, not specified as acute or chronic - J40
Other chronic obstructive pulmonary disease - J44
Asthma - J45
Crohn's disease [regional enteritis] - K50
Ulcerative colitis - K51
Atopic dermatitis - L20
Seborrhoeic dermatitis - L21
Allergic contact dermatitis - L23
Irritant contact dermatitis - L24
Lichen simplex chronicus and prurigo - L28
Other dermatitis - L30
Psoriasis - L40
Psoriasis vulgaris - L40.0
Other acute skin changes due to ultraviolet radiation - L56
Acne - L70
Acne, unspecified - L70.9
Other disorders of skin and subcutaneous tissue, not elsewhere classified - L98
Rheumatoid arthritis with rheumatoid factor - M05
Gout - M10
Other arthritis - M13
Osteoarthritis - M15-M19
Systemic lupus erythematosus (SLE) - M32
Dermatopolymyositis - M33
Other systemic involvement of connective tissue - M35
Ankylosing spondylitis - M45
Other and unspecified soft tissue disorders, not elsewhere classified - M79
Neuralgia and neuritis, unspecified - M79.2
Acute nephritic syndrome - N00
Chronic nephritic syndrome - N03
Nausea and vomiting - R11
Shock, not elsewhere classified - R57
Adverse effects, not elsewhere classified - T78
Encounter for procreative management - Z31
Encounter for assisted reproductive fertility procedure cycle - Z31.83
Indications and usage:
Medrol (Methylprednisolone) tablets are indicated in the following conditions:
Dosage and administration:
The initial dosage of Medrol tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Medrol should be discontinued and the patient transferred to other appropriate therapy.
Dosage forms and strengths:
Medrol (Methylprednisolone) tablets: 2 mg, 4 mg, 8 mg, 16 mg, 32 mg.
Treatment of acute overdosage by methylprednisolone is by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of the corticosteroid may be reduced only temporarily, or alternate day treatment may be introduced.
Systemic fungal infections and known hypersensitivity to components.
In patients on corticosteroid therapy subjected to unusual stress, increased Medrol (Methylprednisolone) tablets dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.
Corticosteroids may mask some signs of infection, and new infections may appear during their use. Infections with any pathogen including viral, bacterial, fungal, protozoan or helminthic infections, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect cellular immunity, humoral immunity, or neutrophil function.
These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. There may be decreased resistance and inability to localize infection when corticosteroids are used.
Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.
Usage in pregnancy
Since adequate human reproduction studies have not been done with corticosteroids, the use of methylprednisolone in pregnancy, nursing mothers or women of child-bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.
Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.
Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered to patients receiving immunosuppressive doses of corticosteroids; however, the response to such vaccines may be diminished. Indicated immunization procedures may be undertaken in patients receiving nonimmunosuppressive doses of corticosteroids.
The use of Medrol tablets in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.
If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.
Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed, to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.
Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.
There is an enhanced effect of corticosteroids, including Methylprednisolone (Medrol) on patients with hypothyroidism and in those with cirrhosis.
Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.
The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.
Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.
Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.
Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.
Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.
Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.
Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect.
Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.
Side effects, adverse reactions:
Most common adverse reactions with Medrol (Methylprednisolone) tablets are:
Fluid and electrolyte disturbances
Impaired wound healing
Suppression of growth in children
Posterior subcapsular cataracts
Increased intraocular pressure
Negative nitrogen balance due to protein catabolism
The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity.
Methylprednisolone (Medrol) may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
The effect of methylprednisolone on oral anticoagulants is variable. There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect.
Information for patients:
Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.
A - Australia
C - Australia (Methylprednisolone Acetate suspension)
C - United States (Risk cannot be ruled out)
Salts and other forms:
Methylprednisolone Hydrogen Succinate
Methylprednisolone Sodium Hemisuccinate
Methylprednisolone Sodium Succinate
Synonyms, international and chemical names:
Aceponato de Metilprednisolona
Methylprednisolone Na Succinate
Brands, generics, trade names:
Advantan - Bayer, BioCSL, CSL, Firma Chun Cheong, Intendis, Invida, Jenapharm, Menarini, Schering, Schering-Plough, The Glory Medicina, Transfarma Medica Indah, Zuellig Pharma
Advantan Fatty Ointment - Bayer
Advantan Fettsalbe - Bayer
Advantan Milch - Bayer
Advantan Milk - Bayer
Depo-Medrate - Pfizer, Zoetis
Depo-Medrol - Pfizer, DKSH Distribution, Dr. Fisher Farma, Institute of Pharmaceutical Research and Technology, LF Asia Distribution, Max India, Perrigo, Primal Chemical, The Glory Medicina, Zoetis, Zuellig Pharma
Depo-Medrone - Pfizer, Institute of Pharmaceutical Research and Technology, MPT Pharma, Zoetis
Depo-Nisolone - Pfizer
Hexilon - Kalbe Farma
Hysone - Saviour Speciality
Ivepred - Sun Pharmaceutical Industries
Lemod-Solu - Hemofarm, Stada
Macpred - Macleods Pharmaceuticals, Macphar, Pushkar Pharmaceuticals
Medexa - Dexa Medica Pharm & Chem, DKSH
Medixon - Ferron, Dexa Medica Pharm & Chem, Ferron, Getz Brothers Philippines, Gracio Med Philippines, Shwe Yadanar Myay
Medrate - Pfizer
Medrol - Pfizer
Medrol Dose Pak - Pfizer
Medrol-A - Pfizer
Medrone - Pfizer, B & S Healthcare, Servipharm, Star Pharmaceuticals
Melpred - Cipla
Melsone - Psychotropics India
Meprelon - Sun-Farm
Mepresone - Dexa Medica Pharm & Chem, Cathay Drug
Mepresso-T - Intas Pharmaceuticals
Methylprednisolon - Acis Arzneimittelvertrieb, Jenapharm
Methylprednisolone - Cadista Pharmaceuticals, Mylan, Sandoz, Sopharma
Metilprednisolon - Teva
Metilprednisolona - Normon Laboratorios, Pisa Laboratorios
Metilprednizolon - Sopharma, Teva
Metipred - Chung Gei Pharma
Metypred - Galenpharma, Orion Pharma, Pharmacor Production, Sotex
Metysolon - Dermapharm
M-PredniHexal - Hexal
Neodrol - Neon Laboratories
Nucort-M - Mankind Pharmaceuticals
Oro-Medrol - Zoetis
Precort - Kocak Farma Ilac
Predace - Micro Labs
Predmet - Sun Pharmaceutical Industries, Milmet Pharma
Predni-M - Lichtenstein Pharmazeutica
Prednol - Mustafa Nevzat Ilac
Prednox - Pyridam Farma, One Pharma
Sanexon - Sanbe Farma
Solomet - Orion Pharma
Solu-Medrol - Pfizer, 2Care4 Medical, Eureco-Pharma, DKSH Distribution, Max India, Orifarm, Primal Chemical, The Glory Medicina, Zoetis, Zuellig Pharma
Stenirol - Guardian Pharmatama
Urbason - Sanofi-Aventis
Urbason Solubile - Sanofi-Aventis
Zempred - Sun Pharmaceutical Industries
APIs used in medicine in combinations with methylprednisolone:
Here is a list of popular medications containing methylprednisolone as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Tablets; Oral; Methylprednisolone 2 mgTablets; Oral; Methylprednisolone 4 mgTablets; Oral; Methylprednisolone 8 mgTablets; Oral; Methylprednisolone 16 mgTablets; Oral; Methylprednisolone 24 mgTablets; Oral; Methylprednisolone 32 mg
||PfizerDKSH DistributionOrifarmPerrigoPhytopharmaPrimal ChemicalTechno DrugsThe Glory MedicinaZoetisZuellig Pharma
||Tablets; Oral; Methylprednisolone 4 mgTablets; Oral; Methylprednisolone 8 mgTablets; Oral; Methylprednisolone 16 mgTablets; Oral; Methylprednisolone 40 mg
||Tablets; Oral; Methylprednisolone 4 mgTablets; Oral; Methylprednisolone 8 mgTablets; Oral; Methylprednisolone 16 mg
||Sun Pharmaceutical Industries
Methylprednisolone main article on Wikipedia: https://en.wikipedia.org/wiki/Methylprednisolone
Methylprednisolone compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Methylprednisolone
Methylprednisolone Acetate compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Methylprednisolone-acetate
Methylprednisolone Sodium Succinate compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Methylprednisolone-sodium-succinate
Methylprednisolone on DrugBank: https://www.drugbank.ca/drugs/DB00959
Methylprednisolone Acetate on DrugBank: https://www.drugbank.ca/salts/DBSALT001157
Methylprednisolone Sodium Succinate on DrugBank: https://www.drugbank.ca/salts/DBSALT001158
Methylprednisolone FAQ on MedlinePlus (revised 09/15/2017): https://medlineplus.gov/druginfo/meds/a682795.html
Methylprednisolone tablets drug label info on DailyMed (revised September 9, 2019): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Methylprednisolone containing drugs on Drugs-About.com: https://drugs-about.com/ing/methylprednisolone.html
Methylprednisolone for sale on Pharma Doctor: https://pharma-doctor.com/methylprednisolone.html
Methylprednisolone international drug names on Drugs.com: https://www.drugs.com/international/methylprednisolone.html
Medrol (Methylprednisolone) tablets official prescribing information from the U.S. FDA (revised July 2018): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Medrol (Methylprednisolone) tablets product information on Pfizer website (revised January 2019): https://www.pfizer.com/products/product-detail/medrol
Solu-Medrol (Methylprednisolone Sodium Succinate) for injection official prescribing information from the U.S. FDA (revised October 2011): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Solu-Medrol (Methylprednisolone Sodium Succinate) for injection product information on Pfizer website (revised 09/2020): https://www.pfizer.com/products/product-detail/solu_medrol
Medrol (Methylprednisolone) consumer information on RxList (revised 5/20/2020): https://www.rxlist.com/medrol-drug/patient-images-side-effects.htm
Medrone (Methylprednisolone) tablets 2 mg and 4 mg package information leaflet from Medicines.org.uk (revised 11/2018): https://www.medicines.org.uk/emc/files/pil.1085.pdf
Revised: June 2021
Home Page |
About Us |
How You Can Help |
Copyright © 2002 - 2021 Noah's Wish, Inc. All rights reserved.